| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6403649 | ABBVIE | Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
Sep, 2012
(11 years ago) | |
| US8017655 | ABBVIE | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
Nov, 2012
(11 years ago) | |
| US8038988 | ABBVIE | Method of enhancing hair growth |
Aug, 2023
(8 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8541466 | ABBVIE | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
Jan, 2021
(3 years ago) | |
| US8906962 | ABBVIE | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
Jan, 2021
(3 years ago) | |
| US9579270 | ABBVIE | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
Jan, 2021
(3 years ago) | |
| US7388029 | ABBVIE | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
Jan, 2022
(2 years ago) | |
| US9216183 | ABBVIE | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
Jan, 2023
(1 year, 3 months ago) | |
| US8986715 | ABBVIE | Method of enhancing hair growth |
Jan, 2023
(1 year, 3 months ago) | |
| US8263054 | ABBVIE | Method of enhancing hair growth |
Jan, 2023
(1 year, 3 months ago) | |
| US8758733 | ABBVIE | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
Jan, 2023
(1 year, 3 months ago) | |
| US9226931 | ABBVIE | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
Jan, 2023
(1 year, 3 months ago) | |
| US8926953 | ABBVIE | Method of enhancing hair growth |
Jan, 2023
(1 year, 3 months ago) | |
| US8632760 | ABBVIE | Method of enhancing hair growth |
Jan, 2023
(1 year, 3 months ago) | |
| US8101161 | ABBVIE | Method of enhancing hair growth |
May, 2024
(29 days from now) | |
| US7351404 | ABBVIE | Method of enhancing hair growth |
May, 2024
(29 days from now) | |
Latisse is owned by Abbvie.
Latisse contains Bimatoprost.
Latisse has a total of 16 drug patents out of which 14 drug patents have expired.
Expired drug patents of Latisse are:
- US8541466
- US8906962
- US9579270
- US7388029
- US9216183
- US8986715
- US8263054
- US8758733
- US9226931
- US8926953
- US8632760
- US6403649
- US8017655
- US8038988
Latisse was authorised for market use on 24 December, 2008.
Latisse is available in solution/drops;topical dosage forms.
Latisse can be used as method of increasing eyelash growth, treatment of hair loss and hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness, method of increasing eyelash growth including length, thickness, darkness and/or number of eyelashes by administering bimatoprost to an eyelid margin, method of increasing eyelash growth with bimatoprost, treatment of hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness, method of increasing growth of hair including eyelashes, treatment of hypotrichosis of the eyelashes by increasing and stimulating their growth including length, thickness and darkness, method of increasing hair growth.
The generics of Latisse are possible to be released after 25 May, 2024.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 24, 2011 |
| M(M-140) | Sep 04, 2017 |
Drugs and Companies using BIMATOPROST ingredient
Market Authorisation Date: 24 December, 2008
Treatment: Method of increasing hair growth; Method of increasing eyelash growth with bimatoprost; Treatment of hair loss and hypotrichosis of the eyelashes by increasing their growth including length, thickness...
Dosage: SOLUTION/DROPS;TOPICAL
LATISSE family patents
